Roots Analysis

FEBRUARY 26, 2024

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. Our Social Media Platform Web: [link] LinkedIn: [link] Twitter: [link] The post Subcutaneous Medications and Drug Delivery Systems appeared first on Blog.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 1, 2023

MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.

Protein 100

Protein Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 22, 2023

The US Food and Drug Administration (FDA) has granted Fast Track designation for Biohaven ’s new anti-myostatin adnectin, taldefgrobep alfa, to treat spinal muscular atrophy (SMA). Taldefgrobep is a complete human anti-myostatin recombinant protein that is developed for lowering free myostatin.

Clinical Trials 246

Clinical Trials Clinical Trials Genetics Protein 246

Drug Discovery World

MAY 25, 2023

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

Pharmaceutical Technology

FEBRUARY 20, 2023

ABN-401 is under clinical development by Abion and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is a triazolopyrazine derivative. Buy the report here.

Protein 100

Protein Clinical Trials Clinical Trials Drugs 100

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Protein 40

Protein Development Genome Genomics 40

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The post Sanofi places $75m bet with ABL on popular Parkinson’s drug target appeared first on.

Antibody 98

Antibody Drugs Protein Licensing 98

Pharmaceutical Technology

JUNE 6, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RNA 100

RNA Protein Antibody Vaccination 100

pharmaphorum

JANUARY 25, 2021

The Mitochondria-Targeted Drug Development Digital Summit (April 27-29) is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic. Don’t miss out!

Development 98

Development Drugs Protein Clinical Development 98

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Additional clinical data from the Phase 2 trial conducted in the U.S. and Australia are expected to be unblinded in Q1 and will be targeted for publication.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Protein 100

Protein Engineer Clinical Trials Clinical Trials 100

pharmaphorum

APRIL 28, 2022

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. Robinson is OMass’ founder and scientific advisor.

Protein 104

Protein Drugs Development Clinical Trials 104

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is administered through oral route.

Production 100

Production Clinical Trials Clinical Trials Development 100

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Drug Discovery World

FEBRUARY 2, 2024

The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million).

Protein 52

Protein DNA Clinical Development Drugs 52

Drug Discovery World

MAY 11, 2023

They are chemically synthesisable, featuring a low molecular weight and tunable pharmacokinetics, with a large surface-area for molecular interactions that allows protein-protein interactions to be targeted. The two companies will jointly use Bicycle’s peptide technology to develop bicyclic peptides for several oncology targets.

Manufacturing 97

Manufacturing Protein Clinical Development Development 97

pharmaphorum

MAY 30, 2022

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions.

Development 52

Development Drugs FDA Approval Clinical Trials 52

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on sympress platform technology.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. According to GlobalData, Phase III drugs for Parkinson’s Disease have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn. Buy the report here.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

JUNE 5, 2023

BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. According to GlobalData, Phase I drugs for Lung Disease have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. (Nasdaq: ARVN) and Pfizer Inc.

Protein 52

Protein Development HR Hormones 52

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit. The post 3rd RNA-Targeted Drug Discovery Summit appeared first on.

RNA 52

RNA Drugs Protein Clinical Development 52

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100